Published in Hepatology on September 01, 1998
Bone density in haemophilia: a single institutional cross-sectional study. Haemophilia (2013) 1.47
Guidelines on the management of osteoporosis associated with chronic liver disease. Gut (2002) 1.40
Reduced bone mineral density and altered bone turnover markers in patients with non-cirrhotic chronic hepatitis B or C infection. World J Gastroenterol (2005) 1.37
Physiologic frailty and fragility fracture in HIV-infected male veterans. Clin Infect Dis (2013) 1.26
Bone mineral density and disorders of mineral metabolism in chronic liver disease. World J Gastroenterol (2009) 1.20
Risk of hip fracture associated with hepatitis C virus infection and hepatitis C/human immunodeficiency virus coinfection. Hepatology (2012) 1.16
Ectopic and serum lipid levels are positively associated with bone marrow fat in obesity. Radiology (2013) 1.12
Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men. AIDS (2009) 1.04
Hepatic osteodystrophy and liver cirrhosis. World J Gastroenterol (2010) 1.01
Current understanding of osteoporosis associated with liver disease. Nat Rev Gastroenterol Hepatol (2009) 1.00
Osteoporosis and fractures in HIV/hepatitis C virus coinfection: a systematic review and meta-analysis. AIDS (2014) 1.00
Hepatic osteodystrophy is common in patients with noncholestatic liver disease. Dig Dis Sci (2011) 0.96
The heterogeneity of bone disease in cirrhosis: a multivariate analysis. Osteoporos Int (2003) 0.96
Classical and emerging roles of vitamin D in hepatitis C virus infection. Semin Liver Dis (2011) 0.94
Hepatic osteodystrophy: An important matter for consideration in chronic liver disease. World J Hepatol (2011) 0.94
Disturbances of parathyroid hormone-vitamin D axis in non-cholestatic chronic liver disease: a cross-sectional study. Hepatol Int (2010) 0.94
Serum vitamin D levels are not predictive of the progression of chronic liver disease in hepatitis C patients with advanced fibrosis. PLoS One (2012) 0.93
Association between serum 25(OH) vitamin D, incident liver cancer and chronic liver disease mortality in the Linxian Nutrition Intervention Trials: a nested case-control study. Br J Cancer (2013) 0.90
Controlled HIV viral replication, not liver disease severity associated with low bone mineral density in HIV/HCV co-infection. J Hepatol (2011) 0.90
Osteoporosis in chronic liver disease: a case-control study. Rheumatol Int (2009) 0.89
Theoretical basis of a beneficial role for vitamin D in viral hepatitis. World J Gastroenterol (2012) 0.88
Total 25(OH) vitamin D, free 25(OH) vitamin D and markers of bone turnover in cirrhotics with and without synthetic dysfunction. Liver Int (2015) 0.86
Crucial Role of Vitamin D in the Musculoskeletal System. Nutrients (2016) 0.85
Hepatic osteodystrophy in rats results mainly from portasystemic shunting. Gut (2003) 0.85
Clinical benefits of biochemical markers of bone turnover in Egyptian children with chronic liver diseases. World J Gastroenterol (2007) 0.83
Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin. Osteoporos Int (2014) 0.81
Clinical manifestations of portal hypertension. Int J Hepatol (2012) 0.81
MELD score, insulin-like growth factor 1 and cytokines on bone density in end-stage liver disease. World J Hepatol (2011) 0.80
Serum sclerostin in hepatitis C virus infected patients. J Bone Metab (2014) 0.79
Bone mineral density and cytokine levels during interferon therapy in children with chronic hepatitis B: does interferon therapy prevent from osteoporosis? BMC Gastroenterol (2005) 0.79
Osteoporosis in liver disease: pathogenesis and management. Ther Adv Endocrinol Metab (2016) 0.78
Bone Mineral Density, Bone Turnover, and Systemic Inflammation in Non-cirrhotics with Chronic Hepatitis C. Dig Dis Sci (2015) 0.78
The effect of HIV-hepatitis C co-infection on bone mineral density and fracture: a meta-analysis. PLoS One (2014) 0.78
Evidence of degraded BMD and geometry at the proximal femora in male patients with alcoholic liver cirrhosis. Osteoporos Int (2014) 0.77
Proton pump inhibitors increase the incidence of bone fractures in hepatitis C patients. Dig Dis Sci (2012) 0.77
Protective Role of Black Tea Extract against Nonalcoholic Steatohepatitis-Induced Skeletal Dysfunction. J Osteoporos (2011) 0.76
Bone disorders in children and adolescents with chronic HCV infection. Clin Cases Miner Bone Metab (2014) 0.75
Metabolic Bone Disease in Viral Cirrhosis: A Prospective Study. ISRN Hepatol (2013) 0.75
Effect of calcitriol supplementation and tail suspension on serum biomarkers of bone formation in rats. J Diabetes Metab Disord (2015) 0.75
Hormonal and cytokine implications in the pathophysiology of osteoporosis occurring in chronic liver diseases. Maedica (Buchar) (2012) 0.75
Effects of cirrhosis on bone mineral density and bone metabolism. Eurasian J Med (2008) 0.75
Use of calcaneal ultrasound and biochemical markers to assess the density and metabolic state of the bones of adults with hepatic cirrhosis. J Natl Med Assoc (2007) 0.75
Insulin-Like Growth Factor-1 Deficiency and Cirrhosis Establishment. J Clin Med Res (2017) 0.75
Diagnosis and Management of Cirrhosis-Related Osteoporosis. Biomed Res Int (2016) 0.75
Chronic non-cholestatic liver disease is not associated with an increased fracture rate in children. J Bone Miner Metab (2010) 0.75
Significant liver fibrosis assessed using liver transient elastography is independently associated with low bone mineral density in patients with non-alcoholic fatty liver disease. PLoS One (2017) 0.75
Risk and adverse outcomes of fractures in patients with liver cirrhosis: two nationwide retrospective cohort studies. BMJ Open (2017) 0.75
Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Fosamax International Trial Study Group. Osteoporos Int (1999) 1.98
Relation between vitamin D insufficiency, bone density, and bone metabolism in healthy postmenopausal women. J Bone Miner Res (2001) 1.23
Bone loss in hyperthyroid patients and in former hyperthyroid patients controlled on medical therapy: influence of aetiology and menopause. Clin Endocrinol (Oxf) (1997) 0.94
Mineral metabolism, osteoblastic function and bone mass in chronic alcoholism. Alcohol Alcohol (1993) 0.92
Effect of raloxifene after recombinant teriparatide [hPTH(1-34)] treatment in postmenopausal women with osteoporosis. Osteoporos Int (2007) 0.90
Antiresorptive therapy in hyperthyroid patients: longitudinal changes in bone and mineral metabolism. J Clin Endocrinol Metab (1997) 0.90
Insulin degludec improves long-term glycaemic control similarly to insulin glargine but with fewer hypoglycaemic episodes in patients with advanced type 2 diabetes on basal-bolus insulin therapy. Diabetes Obes Metab (2014) 0.89
Effect of tobacco consumption on bone mineral density in healthy young males. Calcif Tissue Int (1997) 0.89
Methimazole-induced aplastic anemia in third exposure: successful treatment with recombinant human granulocyte colony-stimulating factor. Thyroid (1998) 0.86
Performance of quantitative ultrasound in the discrimination of prevalent osteoporotic fractures in a bone metabolic unit. Bone (2003) 0.85
Alterations in bone turnover in HIV-positive patients. Infection (1993) 0.84
Relationship between serum levels of osteocalcin and atherosclerotic disease in type 2 diabetes. Diabetes Metab (2011) 0.82
Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner (1993) 0.82
Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int (2013) 0.81
Bone mineral density and bone turnover in non-cirrhotic patients with chronic hepatitis C and sustained virological response to antiviral therapy with peginterferon-alfa and ribavirin. Osteoporos Int (2014) 0.81
Effects of raloxifene therapy on circulating osteoprotegerin and RANK ligand levels in post-menopausal osteoporosis. J Endocrinol Invest (2008) 0.81
Effect of acute alcohol ingestion on mineral metabolism and osteoblastic function. Alcohol Alcohol (1995) 0.80
Bone mineral density, sex steroids, and mineral metabolism in premenopausal smokers. Calcif Tissue Int (1994) 0.80
SHBG levels are associated with bone loss and vertebral fractures in patients with prostate cancer. Osteoporos Int (2012) 0.78
Inhaled steroids do not decrease bone mineral density but increase risk of fractures: data from the GIUMO Study Group. J Clin Densitom (2006) 0.78
Quantitative ultrasound calcaneus measurements: normative data and precision in the spanish population. Osteoporos Int (2002) 0.78
Improved adherence with PTH(1-84) in an extension trial for 24 months results in enhanced BMD gains in the treatment of postmenopausal women with osteoporosis. Osteoporos Int (2012) 0.78
Identification of metabolic bone disease in patients with endogenous hyperthyroidism: role of biological markers of bone turnover. Calcif Tissue Int (1997) 0.78
Postmenopausal women with Colles' fracture have bone mineral density values similar to those of controls when measured with calcaneus quantitative ultrasound. Eur J Intern Med (2005) 0.78
Effects of ethanol administration on rat liver plasma membrane-bound enzymes. Biochem Pharmacol (1985) 0.77
Serum osteoprotegerin: bone or cardiovascular marker in Type 2 diabetes males? J Endocrinol Invest (2012) 0.77
Effects of ethanol and acetaldehyde on hepatic plasma membrane ATPases. Biochem Pharmacol (1983) 0.77
Performance of COLIA1 polymorphism and bone turnover markers to identify postmenopausal women with prevalent vertebral fractures. Osteoporos Int (2002) 0.76
Resection for carcinoma of the lung with metastases. Chest (1980) 0.75
Effect of ketoconazole in the hyperandrogenism, insulin resistance and acanthosis nigricans (HAIR-AN) syndrome. J Am Acad Dermatol (1992) 0.75
Bone mineral density is decreased in hyperthyroidism. Clin Endocrinol (Oxf) (1994) 0.75
Effect of alcohol consumption on adult bone mineral density and bone turnover markers. Alcohol Clin Exp Res (1999) 0.75
[Localization techniques in primary hyperparathyroidism]. Med Clin (Barc) (1993) 0.75
Alcohol and renal phosphate excretion. Gastroenterology (1992) 0.75
Ketoconazole therapy: hormonal and clinical effects in non-tumoral hyperandrogenism. Eur J Endocrinol (1994) 0.75
Postmenopausal women with colles' fracture have lower values of bone mineral density than controls as measured by quantitative ultrasound and densitometry. J Clin Densitom (2005) 0.75
Dehydroepiandrosterone sulfate and other possible influencing factors that modulate sex hormone-binding globulin levels in the hirsute patient. J Steroid Biochem Mol Biol (1992) 0.75
Virilizing mature ovarian cystic teratomas. Virchows Arch (1997) 0.75
[Bone densitometry: clinical applications and scientific evidence]. Rev Clin Esp (2004) 0.75
[Lipid profile of hyperandrogenic women undergoing treatment with ketoconazole and its relationship with the evolution of the hormone pattern]. Med Clin (Barc) (1993) 0.75
Perindopril-induced acute pancreatitis. Dig Dis Sci (1997) 0.75
[Penetrating aortic ulcer: an unreported cause of massive digestive hemorrhage]. Med Clin (Barc) (2000) 0.75
Hyperinsulinemia in polycystic ovary syndrome: relationship to clinical and hormonal factors. Clin Investig (1994) 0.75
Reduction of endogenous, ovarian and adrenal androgens with ketoconazole does not alter insulin response in the polycystic ovary syndrome. J Endocrinol Invest (1994) 0.75
[New approaches to the role of estrogens in bone metabolism]. Med Clin (Barc) (1999) 0.75
[Intracranial hypertension in postoperative hypoparathyroidism]. Med Clin (Barc) (1997) 0.75
[New trends in the definition and diagnostic criteria of polycystic ovary syndrome]. Med Clin (Barc) (1993) 0.75
[Cardiovascular disease, osteoporosis and risk of fracture]. Rev Clin Esp (2011) 0.75
[Elevation of muscular enzymes and idiopathic hypoparathyroidism]. Med Clin (Barc) (1995) 0.75
[Cholestatic hepatitis by josamycin]. Gastroenterol Hepatol (1999) 0.75